Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM01 versus placebo and epoetin beta for chemotherapy-associated anaemia in patients with solid tumours
ISRCTN09530309Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of epoetin theta in anaemia and Nonhematologic neoplasms (3 arms), sponsored by BioGeneriX AG. Primary endpoint: Complete haemoglobin response. Started Oct 2005; status: completed.
02
Drugs
epoetin theta
03
Conditions
anaemiaNonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN09530309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN09530309.